MARKET

CYCC

CYCC

Cyclacel Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4832
+0.0531
+12.35%
Opening 14:44 11/21 EST
OPEN
0.4300
PREV CLOSE
0.4301
HIGH
0.4840
LOW
0.4300
VOLUME
197.89K
TURNOVER
--
52 WEEK HIGH
1.180
52 WEEK LOW
0.2813
MARKET CAP
8.31M
P/E (TTM)
-0.8207
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CYCC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CYCC News

  • Edited Transcript of CYCC earnings conference call or presentation 13-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.4d ago
  • The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
  • Benzinga.11/14 13:07
  • Cyclacel Pharmaceuticals EPS beats by $0.04
  • seekingalpha.11/14 02:09
  • Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/13 23:38

More

Industry

Biotechnology & Medical Research
-0.44%
Pharmaceuticals & Medical Research
+0.31%

Hot Stocks

Name
Price
%Change

About CYCC

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.
More

Webull offers Cyclacel Pharmaceuticals Inc (CYCC) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.